Treatment Augmentation After adjustment, approximately one-third of DPP4i users added a new glucose-lowering drug class compared with approximately one-fifth of semaglutide users during the 2-year follow-up (31.8% vs 19.3%, respectively
Underlying mechanisms involve improved glycemic control, but also increased nitric oxide bioavailability, reduced oxidative stress and, for certain molecules, a direct inhibition of platelet activation and aggregation
Available from: Knop FK, Aroda VR, Do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al
She walked through the big ones
Some people find it easier on the digestive system than heavier fruits, which can matter when gastrointestinal side effects are present
Baseline confounders were balanced using propensity score matching